Liver Ischemia-reperfusion Injury and Clinical Data Analysis
Sponsor
Qin Zhang (Other)
Overall Status
Recruiting
CT.gov ID
NCT06080308
Collaborator
(none)
270
1
11.7
23.1
Study Details
Study Description
Brief Summary
Searching for new targets for the diagnosis and treatment of liver ischemia-reperfusion injury.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Through the analysis of serological data during liver resection elective surgery with hepatic pedicle occlusion and reperfusion, as well as the analysis of patient-related data, we aim to identify key target points that affect reperfusion injury and explore their underlying mechanisms.
Study Design
Study Type:
Observational
Anticipated Enrollment
:
270 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Research on the Molecular Mechanisms of Liver Ischemia-reperfusion Injury and Clinical Data Analysis: an Observational Study
Anticipated Study Start Date
:
Oct 10, 2023
Anticipated Primary Completion Date
:
Dec 20, 2023
Anticipated Study Completion Date
:
Sep 30, 2024
Outcome Measures
Primary Outcome Measures
- Length of hospital stay [7days]
Length of hospital stay
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 70 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
- Willingness to participate in the study and has signed an informed consent form. 2) Age ≥ 18 years and ≤ 70 years. 3) ASA classification ≤ III. 4) Criteria for liver ischemia-reperfusion injury patients: patients undergoing elective liver resection surgery with hepatic pedicle occlusion and reperfusion during the procedure.
Exclusion Criteria:
- Patients with adverse events during surgery. 2) Patients in the end stage of disease with liver failure. 3) Liver tumor metastasis with concomitant severe heart failure or chronic renal insufficiency, etc. 4) Deemed unsuitable for participation in the study based on the judgment of the researchers.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | China | 430030 |
Sponsors and Collaborators
- Qin Zhang
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Qin Zhang,
phd,
Tongji Hospital
ClinicalTrials.gov Identifier:
NCT06080308
Other Study ID Numbers:
- TJ-IRB20230940
First Posted:
Oct 12, 2023
Last Update Posted:
Oct 12, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Qin Zhang,
phd,
Tongji Hospital
Additional relevant MeSH terms: